IL17 Rate and Spondyloarthritis

Recruiting now

Conditions studied: Spondylarthritis

In brief

There are, to date, no validated biomarkers or head-to-head RCTs of biologics to guide choice of biologic agent in axSpA. While there are now two head-to-head studies of a TNF inhibitor (TNFi) vs an IL-17 inhibitor (IL-17i) in psoriatic arthritis. Recommendations refers to biological DMARDs (bDMARDs) including TNFi and IL-17i for patients with high disease activity despite the use (or intolerance/contraindication) of at least two non-steroidal anti-inflammatory drugs (NSAIDs) in axial SpA (axSpA) and in failure of a strategy including methotrexate for psoriatic arthritis. A tool to help us to decide which bDMARDs to use is necessary. In SpA, the method of determination of IL17 seems to be questionable. The determination of cytokines after stimulation of immune cells in patients with active SpA requiring a biological treatment could provide us with a tool to assist in the choice of therapy. The aim of the study was to show the feasibility of cytokine assay following lymphocyte stimulation in active SpA requiring biological treatment. And secondly, to show the predictive character of this expression on the therapeutic response at three months after the implementation of a biological treatment.

Key facts

Study ID

NCT05592574

Run by

Centre Hospitalier Universitaire de Nice

People needed

50

Starts

2021-02-01

Expected to finish

2041-01-31

Last updated by the study team

2022-10-24

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with spondyloarthritis meeting the ASAS criteria
• Patients who were to benefit from the implementation of a biological treatment after failure of at least two NSAIDs.
• Patients having an active disease defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) higher than four,

You may not qualify if…

• No predominant axial manifestation,
• Having received a previous biological treatment
• Patients presenting contraindication to the implementation of these treatments.

Where it is running

• CHU de NICE — Nice, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.